Sarepta EVP has 408 shares withheld for taxes

Sarepta Therapeutics EVP and General Counsel Cristin Rothfuss reported a small share disposition for tax withholding purposes.

Rhea-AI Filing Summary

Sarepta Therapeutics EVP and General Counsel Cristin Rothfuss reported a small share disposition for tax withholding purposes. On March 2, 2026, 408 shares of Sarepta common stock were withheld by the company at $16.20 per share to cover taxes on restricted stock units that vested from a grant made on March 1, 2024. After this tax-withholding transaction, Rothfuss’s directly held ownership stood at 139,348 shares of common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 408 shares

Exercise Price or Tax Liability 1 txn

Insider Rothfuss Cristin

Role EVP, General Counsel

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	408	$16.20	$7K

Holdings After Transaction: Common Stock — 139,348 shares (Direct)

Footnotes (1)

1. F1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sarepta Therapeutics (SRPT) report for Cristin Rothfuss?

Sarepta reported that EVP and General Counsel Cristin Rothfuss had 408 common shares withheld on March 2, 2026 to satisfy tax obligations on vested restricted stock units. This is a tax-withholding disposition rather than an open-market share sale.

Was the Sarepta (SRPT) insider transaction an open-market sale of shares?

No, the transaction was not an open-market sale. The company withheld 408 shares from Cristin Rothfuss to cover tax withholding obligations related to previously granted restricted stock units that vested, according to the Form 4 footnote.

How many Sarepta (SRPT) shares were involved in Cristin Rothfuss’s Form 4 filing?

The Form 4 shows 408 shares of Sarepta common stock were disposed of through tax withholding at $16.20 per share. These shares were withheld by the company to satisfy tax obligations tied to vesting restricted stock units granted on March 1, 2024.

What is Cristin Rothfuss’s Sarepta (SRPT) share ownership after this Form 4 transaction?

After the tax-withholding disposition, Cristin Rothfuss directly owns 139,348 shares of Sarepta common stock. This balance reflects the remaining shares following the 408-share withholding to meet tax obligations from the restricted stock unit vesting event.

Why did Sarepta (SRPT) withhold shares from Cristin Rothfuss in this Form 4?

Shares were withheld to satisfy tax withholding obligations triggered by the vesting of restricted stock units granted on March 1, 2024. Instead of paying taxes in cash, 408 shares were retained by Sarepta to cover the required tax amount.

What type of insider transaction code is shown in the Sarepta (SRPT) Form 4?

The Form 4 uses transaction code F, which indicates payment of tax liability or exercise price by delivering securities. In this case, 408 shares of Sarepta common stock were withheld to cover taxes on vested restricted stock units held by Cristin Rothfuss.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rothfuss Cristin

(Last) (First) (Middle)

215 FIRST STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		F(1)		408	D	$16.2	139,348	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.

	/s/ Cristin L. Rothfuss	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.